Pregabalin in patients with post‐traumatic peripheral neuropathic pain: A meta‐analysis of randomized controlled trials
Pain Practice · 2023
DOI: 10.1111/papr.13221 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Pain Practice, 2023. Verfasst von Mohsen Saheban Maleki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bohlool Hospital, Gonabad University of Medical Sciences, Gonabad, Iran. Hauptthemen laut MEDLINE: Analgesics, Neuralgia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Objective
The aim of the study was to investigate the safety and efficacy of pregabalin versus placebo in post‐traumatic peripheral neuropathic pain (PTNP).
Methods
PubMed, Cochrane Library, Web of Science, and Google Scholar were searched for relevant evidence up to January 2022. The Cochran tool was used to assess the quality of randomized clinical trials (RCTs). Data analysis was performed using Comprehensive Meta‐Analysis software.
Results
Three RCTs involving 821 patients were included in the meta‐analysis. A significant difference was observed between pregabalin and placebo in terms of the pain score (the standardized mean difference [SMD] = −0.14, 95% CI: 0.28 to −0.006, p = 0.04) and sleep interference (MD = −0.25, 95% CI: −0.39 to −0.11, p = 0.00). There was also a significant difference between pregabalin and placebo regarding somnolence (risk ratio [RR] = 2.78; 95% CI: 1.64–4.71, p = 0.00), dizziness (RR = 4.13; 95% CI: 2.71–6.28, p = 0.00), and disturbance in attention (RR: 2.97; 95% CI: 1.02–8.65, p = 0.04). However, no significant difference was observed between pregabalin and placebo in terms of headache (RR = 1.20; 95% CI: 0.70–2.06, p = 0.50), fatigue (RR = 1.42; 95% CI: 0.82–2.47, p = 0.20), nausea (RR = 1.52; 95% CI: 0.88–2.62, p = 0.13), constipation (RR = 1.84; 95% CI: 0.78–4.29, p = 0.15), and discontinuation (RR = 1.52; 95% CI: 0.45–5.06, p = 0.49).
Conclusion
Compared with placebo, pregabalin showed better efficacy in reducing PTNP and improving sleep interference. However, it was associated with higher adverse events. Further RCTs are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bohlool Hospital, Gonabad University of Medical Sciences, Gonabad, Iran.
- Nursing Care Research Center, Semnan University of Medical Sciences, Semnan, Iran.
- Department of Intensive Care Nursing, Kish Specialty & Subspecialty Hospital, Kish, Iran.
- Department of Clinical Biochemistry, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
- Department of Nursing, School of Nursing and Midwifery, Bam University of Medical Sciences, Bam, Iran.
- Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Maleki, M. S., Zamani, Z., Amiri, R., Kakhki, S., Jafari, M., Amani, B., Amani, B., & Amanat, N. (2023). Pregabalin in patients with post‐traumatic peripheral neuropathic pain: A meta‐analysis of randomized controlled trials. Pain Practice. https://doi.org/10.1111/papr.13221
Vancouver
Maleki MS, Zamani Z, Amiri R, Kakhki S, Jafari M, Amani B, et al. Pregabalin in patients with post‐traumatic peripheral neuropathic pain: A meta‐analysis of randomized controlled trials. Pain Practice. 2023. doi:10.1111/papr.13221
BibTeX
@article{Maleki2023,
author = {Maleki, Mohsen Saheban and Zamani, Zahra and Amiri, Roya and Kakhki, Samaneh and Jafari, Mojtaba and Amani, Behnam and Amani, Bahman and Amanat, Nasir},
title = {Pregabalin in patients with post‐traumatic peripheral neuropathic pain: A meta‐analysis of randomized controlled trials},
journal = {Pain Practice},
year = {2023},
doi = {10.1111/papr.13221}
}
EUVIMED